Aurobindo Partners with Global Pharma for Respiratory Products
By Rediff Money Desk, New Delhi Nov 23, 2024 18:31
Aurobindo Pharma's US subsidiary has partnered with a global pharma company to develop and commercialize respiratory products. The partnership involves a cost-sharing agreement and global manufacturing rights.
New Delhi, Nov 23 (PTI) Aurobindo Pharma on Saturday said its US-based subsidiary has inked a licensing agreement with a global pharma major for development of respiratory products.
Aurobindo Pharma USA Inc has entered into a collaboration and licence agreement with a global pharma major for development and commercialisation of products, the Hyderabad-based drug firm said in a regulatory filing.
The partnership is for an initial estimated development duration of three-five years, it added.
As per the pact, both parties will co-exclusively commercialise the products.
The products, once commercialised, will be manufactured at Partner's facility and will be marketed by both parties, Aurobindo Pharma said.
Besides a cost-sharing arrangement has been agreed by both the parties with each of them contributing 50 per cent of the cost incurred with an overall cap of USD 90 million for Aurobindo over the development period, it said.
As per the pact, the unnamed global pharma company will have the global manufacturing rights for the co-developed and commercialised products, it said.
Aurobindo Pharma USA Inc has entered into a collaboration and licence agreement with a global pharma major for development and commercialisation of products, the Hyderabad-based drug firm said in a regulatory filing.
The partnership is for an initial estimated development duration of three-five years, it added.
As per the pact, both parties will co-exclusively commercialise the products.
The products, once commercialised, will be manufactured at Partner's facility and will be marketed by both parties, Aurobindo Pharma said.
Besides a cost-sharing arrangement has been agreed by both the parties with each of them contributing 50 per cent of the cost incurred with an overall cap of USD 90 million for Aurobindo over the development period, it said.
As per the pact, the unnamed global pharma company will have the global manufacturing rights for the co-developed and commercialised products, it said.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 9.12 (+ 2.13)
- 64303795
- G G Engineering
- 1.51 ( -5.63)
- 28492226
- Guj. Toolroom Lt
- 15.37 (+ 4.99)
- 19678431
- Srestha Finvest
- 0.69 ( -1.43)
- 14826074
- AvanceTechnologies
- 0.80 ( -2.44)
- 14124154
MORE NEWS
Tulip Hotels Liquidated by NCLT After Failing...
NCLT has ordered the liquidation of Tulip Hotels after the company failed to secure a...
Rupee to Stabilize Around 85-86/USD: Deloitte
The Indian rupee is expected to appreciate slightly and stabilize around 85-86 per...
Tripura Surpasses Rubber Plantation Target:...
Tripura has exceeded its 5-year rubber plantation target of 30,000 hectares, aiming for...